Meeting
2015 Breast Cancer Symposium
Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial.
Authors
Arlene Chan
Breast Cancer Research Centre - WA & Curtin University, Perth, Australia
Arlene Chan , Miguel Martin , Gunter Von Minckwitz , Bent Ejlertsen , Stephen K. L. Chia , Marc E. Buyse , Janine Mansi , Michael Gnant , Frankie Ann Holmes , Beverly Moy , Hiroji Iwata , Alvin Wong , Alshad S. Lalani , Richard Bryce , Judith D Bebchuk , Suzette Delaloge
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Systemic Therapy, Survivorship, and Health Policy
Track
Systemic Therapy,Local/Regional Therapy,Survivorship and Health Policy
Sub Track
HER2+
Clinical Trial Registration Number
NCT00878709
Citation
J Clin Oncol 33, 2015 (suppl 28S; abstr 117)
DOI
10.1200/jco.2015.33.28_suppl.117
Abstract #
117
Poster Bd #
A4
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Timing of initiation of neratinib after trastuzumab-based adjuvant therapy in early‑stage HER2+ hormone receptor (HR)-negative breast cancer: Exploratory analyses from the phase III ExteNET trial.
First Author: Bent Ejlertsen
Poster
2021 ASCO Annual Meeting
Association between treatment duration and overall survival in early-stage HER2+ breast cancer patients receiving extended adjuvant therapy with neratinib in the ExteNET trial.
First Author: Beverly Moy
Poster
2019 ASCO Annual Meeting
Is neratinib following trastuzumab in early-stage HER2-positive breast cancer cost-effective?
First Author: Naomi RM Schwartz
Poster
2018 ASCO Annual Meeting
Duration of extended adjuvant therapy with neratinib in early‑stage HER2+ breast cancer after trastuzumab-based therapy: Exploratory analyses from the phase III ExteNET trial.
First Author: Michael Gnant